clinical trial · NCT05975099
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
ModernaTX, Inc.·phase2·completed·n = 807
Lyme DiseasemRNA-1975mRNA-1982Placebo
brief summary
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
started
Jul 26, 2023
primary completion
May 30, 2025
completion
May 30, 2025
last updated
Aug 22, 2025
official title
A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol